Clinical trials
Advanced Lung Cancer clinical trials
Below are recruiting advanced lung cancer clinical trials, each written for real people, not researchers. We’re tracking 1,300 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06498648RecruitingPhase 1/Phase 2
Abemaciclib with gemcitabine for soft tissue sarcoma
This trial tests whether adding the targeted drug abemaciclib to standard chemotherapy (gemcitabine) works better against certain soft tissue sarcomas. It is for people whose tumors have a normal Rb gene, which may help the drug work.
Houston, TexasAges 18 years+ - NCT05628922RecruitingPhase 2
Blood EBV DNA–guided therapy for advanced nasopharyngeal cancer
This trial tests a treatment approach for people with locally advanced nasopharyngeal cancer using their blood EBV DNA level (a cancer-related virus marker). It may help doctors choose and adjust therapy based on how much of this marker is in your blood after standard treatment.
Shanghai, Shanghai MunicipalityAges 18–70 - NCT07314216RecruitingPhase 2
Firmonertinib plus radiation for stage III lung cancer with rare EGFR mutations
This trial tests whether combining the targeted pill firmonertinib with radiation therapy can help people with stage III non-small cell lung cancer that has certain rare EGFR mutations. It is for those whose cancer cannot be removed by surgery.
Changsha, HunanAges 18 years+ - NCT07007273RecruitingPhase 2
Pembrolizumab for advanced skin sarcomas (not angiosarcoma)
This trial is testing a drug called pembrolizumab (Keytruda) for people with advanced soft tissue sarcomas that started in the skin. The goal is to see if this immunotherapy can help shrink or slow the growth of these tumors.
Tampa, FloridaAges 18 years+ - NCT05039632RecruitingPhase 1/Phase 2
NBTXR3 plus radiation with anti-PD-1 for advanced lung or liver cancers
This study tests whether adding NBTXR3 (given into a tumor) and targeted radiation to anti–PD-1/PD-L1 immunotherapy can improve cancer control in advanced cancers that have spread to the lung and/or liver. Participants may be assigned to different radiation approaches to try to trigger tumor shrinkage in both treated and nearby or distant tumor areas.
Houston, TexasAges 18 years+ - NCT07440290RecruitingPhase 2/Phase 3
Dabrafenib and trametinib for BRAF V600 cancers
This trial tests two targeted drugs (dabrafenib and trametinib) for patients whose cancer has a specific change in the BRAF gene called V600. These drugs work together to block signals that help the cancer grow. The trial is for children, teenagers, and adults with many types of cancer, except for a few common ones that already have approved treatments.
BelfastAges 1 year+ - NCT06093061RecruitingPhase 2
Maintenance therapy for high-risk nasopharyngeal cancer
This trial tests a combination of two drugs—tislelizumab (an immunotherapy that helps your immune system fight cancer) and capecitabine (a chemo pill taken daily)—as maintenance therapy after initial chemotherapy for high-risk nasopharyngeal cancer. The goal is to see if this approach can lower the chance of cancer coming back.
SingaporeAges 21–99 - NCT05786716RecruitingPhase 2/Phase 3
Trastuzumab plus pertuzumab for HER2-mutated cancers
This trial tests whether combining trastuzumab and pertuzumab can treat cancers that have HER2 amplification or an activating HER2 mutation. It looks at people ages 12 and older, and may include both children/teens and adults, using the study drug based on their HER2 test results.
BelfastAges 12 years+ - NCT05665361RecruitingPhase 1/Phase 2
Testing palbociclib plus sasanlimab for advanced kidney cancers
This study tests a combination of two medicines—palbociclib and sasanlimab—in people with advanced clear cell or papillary kidney cancer. It’s mainly designed to check safety (and early signs of how well the treatment may work) in these cancer types.
Bethesda, MarylandAges 18–100 - NCT06211114RecruitingPhase 2
Immunotherapy and targeted drug for advanced collecting duct kidney cancer
This trial tests a combination of immunotherapy and a targeted drug (axitinib) for people with advanced collecting duct carcinoma, a rare type of kidney cancer. The goal is to see if this treatment can shrink tumors or slow the cancer's growth.
Beijing, Beijing MunicipalityAges 18–80 - NCT07457528RecruitingPhase 2
Chemo, radiation, and immune therapy before surgery for esophageal cancer
This trial tests a combination of chemotherapy, radiation, and two targeted drugs (serplulimab and nimotuzumab) given before surgery for a certain type of esophageal cancer. It aims to see if this approach can safely improve outcomes.
Tianjin, Tianjin MunicipalityAges 18–75 - NCT06751329RecruitingPhase 1/Phase 2
Study of DM002 for advanced solid tumors
This trial tests a new drug called DM002 for people with advanced solid tumors that have not responded to standard treatments. The drug targets two proteins (MUC1 and HER3) found on some cancer cells, and may help shrink tumors or slow their growth.
San Francisco, CaliforniaAges 18 years+ - NCT06720987RecruitingPhase 1
KQB365 for advanced solid tumors with KRAS mutations
This trial tests a new drug called KQB365, alone or with other drugs, for people with advanced solid tumors that have a specific KRAS mutation (G12C or G12S). It aims to see if the treatment is safe and effective.
Phoenix, ArizonaAges 18 years+ - NCT06027086RecruitingPhase 1/Phase 2
Combination drug therapy for advanced fibrolamellar carcinoma
This trial tests a new combination of two drugs—DRP-104 and durvalumab—to see if they can shrink or slow advanced fibrolamellar carcinoma, a rare liver cancer. It is for patients whose cancer has gotten worse even after immunotherapy treatment.
Baltimore, MarylandAges 12 years+ - NCT07395479RecruitingEarly Phase 1
CAR-T therapy study for advanced blood and solid cancers
This trial tests a new CAR-T therapy designed to target specific proteins on cancer cells. It may be an option for people with advanced blood cancers (like multiple myeloma or lymphoma) or solid tumors (like small cell lung cancer) that have not responded to other treatments.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06705127RecruitingPhase 2
Radiation, chemo, and immunotherapy for HR+ breast cancer
This trial tests if giving radiation first, then chemo with an immunotherapy drug called Toripalimab, can help treat a certain type of breast cancer that has not spread to other organs. It is for people with hormone receptor positive, HER2 negative breast cancer that is growing fast.
Hangzhou, ZhejiangAges 18–75 - NCT07514065RecruitingPhase 1
TSL2109 Safety and Effectiveness Study in Advanced Cancers
This early-stage study tests a new drug called TSL2109 in patients with advanced solid cancers that haven't responded to standard treatment. Researchers want to find the right dose, understand how the body processes it, and see if it can slow or shrink tumors, with special focus on certain prostate and breast cancers.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT06469944RecruitingPhase 1/Phase 2
Study of drug combinations for stomach or esophagus cancer
This trial tests new combinations of drugs alongside standard chemotherapy for people with advanced stomach or esophagus cancer that has not been treated yet. It aims to see if these combinations can shrink tumors or slow down the cancer better than current options.
Tucson, ArizonaAges 18 years+ - NCT06400472RecruitingPhase 1
Study of drug Sofe-M for advanced solid tumors
This trial tests a new drug (Sofe-M) for people with certain advanced solid tumors, including ovarian, endometrial, cervical, lung, breast, pancreatic, or colorectal cancers. The goal is to find the best dose and see how well it works, potentially offering a new treatment option.
Scottsdale, ArizonaAges 18 years+ - NCT05377034RecruitingPhase 2
Y-90 and immunotherapy vs Y-90 plus placebo for liver cancer
This phase 2 study tests whether adding immunotherapy drugs (atezolizumab and bevacizumab) after Y-90 treatment works better and is safe compared with Y-90 followed by placebo. It is for people with liver cancer that has not spread outside the liver but is difficult to treat.
BeijingAges 21–99 - NCT07510334RecruitingPhase 2
VSV Virus Plus Immunotherapy for Advanced Kidney Cancer
This trial tests a combination of a special virus (VSV-IFNβ-NIS) with two immunotherapy drugs (ipilimumab and nivolumab) for people with advanced clear cell kidney cancer that hasn't been treated yet. It aims to see if this approach helps shrink tumors or slow the disease.
Rochester, MinnesotaAges 18 years+ - NCT06084481RecruitingPhase 1
Study of a new drug for advanced solid tumors
This study tests a new intravenous drug called ABBV-400 in people with certain advanced solid tumors that have not responded to other treatments. The goal is to see if it can slow or stop tumor growth and to check for side effects.
Duarte, CaliforniaAges 18 years+ - NCT04807673RecruitingPhase 3
Pembrolizumab before surgery versus chemoradiation for esophageal cancer
This Phase 3 study compares two treatment plans before surgery for locally advanced esophageal squamous cell carcinoma. It tests whether adding pembrolizumab (an immune therapy) to chemotherapy improves outcomes compared with standard chemoradiation.
Tianjin, Tianjin MunicipalityAges 18–75 - NCT07665190RecruitingPhase 2
New drug combination before surgery for advanced throat cancer
This trial tests a new combination of a targeted therapy (EGFR-ADC) and an immunotherapy drug before surgery to shrink and control locally advanced throat cancer. It may help make surgery more effective and reduce the chance of recurrence.
Tianjin, Tianjin MunicipalityAges 18 years+
Hear when a new Advanced Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for advanced lung cancer?
- Yes. Clin2 currently lists 1,300 recruiting advanced lung cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a advanced lung cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a advanced lung cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- NSCLC (Advanced Non-small Cell Lung Cancer)
- Non Small Cell Lung Cancer
- Locally Advanced Non-Small Cell Lung Cancer
- Locally Advanced or Metastatic Non-small Cell Lung Cancer
- Advanced or Metastatic Non-small Cell Lung Cancer
- Lung Cancer (Locally Advanced or Metastatic)
- Lung Cancer Non-Small Cell Cancer (NSCLC)
- EGFR Mutant Advanced Non-small Cell Lung Cancer
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.